Washington State Department of Health (DOH)

Latent Tuberculosis Infection

A Quick Guide to Case Management

DOHTB Program

2014



Table of Contents

Introduction	2
Diagnosing Latent TB Infection Flow Chart	3
Section One: Diagnosing TB Infection	
How to Interpret a Tuberculin Skin Test Reaction	5
Labs Available to Perform IGRA Testing	7
TB Testing Risk Assessment Form	9
Tuberculosis Laboratory Diagnostics Summary	11
Section Two: Initiating Treatment	12
Latent Tuberculosis Infection (LTBI) Treatment Regimens	13
Consent for LTBI Treatment	16
Section Three: Case Management	18
LTBI Case Management: Monthly Patient Assessment	
Section Four: Dispositioning the Patient	22
Tuberculosis Treatment Summary	23
Section Five: Additional Resources	24

Introduction


This guide is intended for providers who care for individuals who have or may be at risk for latent tuberculosis infection (LTBI). LTBI is the presence of *Mycobacterium tuberculosis* in the body without signs and symptoms, or radiographic or bacteriologic evidence of tuberculosis (TB) disease.

In the United States, an estimated 9-14 million people have LTBI. Without treatment, approximately 5-10% of persons with LTBI will progress to TB disease at some point in their lifetime unless LTBI therapy is initiated. Identifying and treating those at highest risk for TB disease will help move toward elimination of the disease.

This document is not meant to be used as a substitute for the comprehensive guidelines published by the Centers for Disease control and Prevention (CDC) and by Washington State Department of Health (DOH), but rather as a ready and useful reference that highlights the main points of those guidelines.

In this document you will find summarization of the main topics related to LTBI diagnosis and case management, links to useful tools and resources, as well as sample forms that can be modified for use by your facility.

Diagnosing Latent TB Infection



Section One: Diagnosing TB Infection

Tests for TB Infection

Tuberculin Skin Test (TST)

The tuberculin skin test is administered intradermally using the Mantoux technique by injecting 0.1 ml of 5 TU purified protein derivative (PPD) solution. If a person is infected, a delayed-type hypersensitivity reaction is detectable 2-8 weeks after infection. The reading and interpretation of TST reactions should be conducted within 48 to 72 hours of administration by a trained health care professional.

Online training on administration of the TST using the Mantoux method is available at: http://www2c.cdc.gov/podcasts/player.asp?f=3739

Key Points

- Almost everyone can receive a TST, including infants, children, pregnant women, people living
 with HIV, and people who have had a BCG vaccination. People who had a severe reaction to a
 precious TST should not receive another TST.ⁱⁱ
- The TST should not be performed on a person who has written documentation of either a previous positive TST result or treatment for TB disease. Once positive, a TST will likely always react positive on subsequent testing.
- Interpretation of the TST result is the same for persons who have had BCG vaccination.
- A positive TB test indicates that a person has been infected with TB, but does not differentiate between latent and active TB. ii

$How to \,Interpret\, a\, Tuberculin\, Skin\, Test\, Reaction$

Induration Size	Considered Positive In:
5 mm or more	 HIV-infected persons Recent contacts of a person with infectious TB disease Persons with fibrotic changes on chest radiograph consistent with prior TB Organ transplant recipients Persons who are immunocompromised for other reasons (e.g., taking equivalent of > 15 mg/day of prednisone for 1 month or more or those taking TNF-alpha antagonisits)
10 mm or more	 Foreign-born persons from countries with a high TB incidence or prevalence (e.g., most countries in Africa, Asia, Latin America, Eastern Europe, the former USSR, or from refugee camps) Injection drug user's Residents and employees in high-risk, congregate settings (e.g., correctional institutions; long-term residential care facilities, such as nursing homes, mental institutions, etc.; hospitals and other healthcare facilities; homeless shelters; and refugee camps) Mycobacteriology laboratory personnel Persons with other medical conditions that increase the risk of TB disease (e.g., diabetes, chronic renal failure or on hemodialysis, head and neck cancer) Children younger than 4 years of age, or children and adolescents exposed to adults in at high risk for TB disease
15 mm or more	Persons with no known risk factors for TB

BCG Vaccine

The BCG vaccine is currently used in many parts of the world where TB is common to protect infants and young children from serious, life-threatening disease. BCG vaccination is not recommended in the U.S. The question of the effect of BCG vaccine on TST results often causes confusion. TST reactivity caused by BCG vaccine generally wanes with the passage of time, but periodic skin testing may prolong (boost) reactivity in vaccinated persons. A history of BCG vaccination is not a contraindication for tuberculin skin testing or treatment for LTBI in persons with positive TST results. TST reactions should be interpreted regardless of BCG vaccination history.

Interferon-Gamma Release Assays (IGRAs) use *M.tuberculosis* specific antigens that do not cross react with BCG and therefore, do not cause false positive reactions in BCG recipients.

Interferon – Gamma Release Assays (IGRAs)

Like the TST, IGRAs are used to determine if a person is infected with *M. tuberculosis*. The QuantiFERON®- TB Gold In-Tube test (QFT-GIT), and T-SPOT.®- *TB* are the two available IGRA tests. The advantages of IGRAs include that they are unaffected by BCG and most environmental mycobacteria, and that a positive and negative control is built into the test which minimizes false positive and negative results.¹

For more information on QFT-GIT and T-SPOT see: www.quantiferon.com and www.tspot.com

Key Points

- Blood samples must be processed within 8-16 hours.
- Blood samples must be collected using specific tubes and collection technique.
- Limited data exist on use in children younger than 5 years of age.
- IGRAs do not cross react with BCG vaccine.ⁱ
- Once positive, an IGRA will likely always react positive on subsequent testing.

Labs Available to Perform IGRA Testing

Evergreen Hospital

12040 NE 128th St Kirkland, WA 98034 Ph: 425-899-3900 Fax: 425-899-3901

Group Health

Locations throughout Washington. Click on link to find the nearest medical center.

LabCorp-Northwest Region

Locations throughout Washington. Click on link to find the nearest laboratory.

Overlake Hospital Medical Center

1135 116th Ave NE Ste 170 Bellevue, WA 98004 425-688-5106

Paclab Network Laboratories

Click on link to find the nearest laboratory. 425-688-9274

<u>PAML – Pathology Associates</u> <u>Medical Laboratories</u>

110 W Cliff Ave Spokane, WA 99204 PAML Client Services (statewide): 800-541-7891

Bellevue/Seattle: 888-472-2522 Olympia: 888-910-6156

Fax: 509-924-0002

Courier Services: 800-541-7891

Providence Everett

916 Pacific Avenue Everett, WA 98201 425-261-2000

<u>Providence St. Peter Hospital</u> Clinical Laboratory

413 Lilly Road NE Olympia, WA 98506 360-493-5181

Public Health - Seattle and King County

325 Ninth Ave Seattle, WA 98104 Ph: 206-744-8950 Fax: 206-731-8963

Quest Diagnostics

1737 Airport Way S, Suite 200 Seattle, WA 1-866-697-8378

Seattle Children's

4800 Sand Point Way NE Seattle, WA 98105 866-987-2000 (Toll Free)

<u>Tacoma General Hospital</u> (Laboratories Northwest)

1003 South 5th – 4th Floor Tacoma, WA 98405 253-403-1187

Tri-Cities Laboratory

7131 West Grandridge Blvd. Kennewick, WA 99336 509-736-0100

UW Medical Center

1959 NE Pacific St Seattle, WA 98195 206-598-6131 UW MC Fax 206-598-7937 Harborview Fax: 206-744-4850

Selecting a Test to Detect TB Infection

- IGRAs are the preferred method of testing for:
 - --Groups of people who have poor rates of returning to have the TST read
 - --Persons who have received BCG vaccine
- TST is the preferred method for testing for:
 - --Children under the age of 5 years
- Either TST or IGRA may be used without preference for other groups that are tested for LTBI.

For more information on selecting a test for TB infection please see:

http://www.cdc.gov/mmwr/pdf/rr/rr5905.pdf

Key Point

• Routine testing with both TST and IGRAs is **NOT** recommended.

At the time of testing the person should be evaluated for risk of TB infection and disease, symptoms of TB disease, and any TB history such as prior positive TB tests and completion of TB therapy. A thorough risk assessment will help in choosing a testing method, interpreting TB test results, and provide useful information regarding potential treatment options.

The following form is an example TB risk assessment form:

TB Testing Risk Assessment Form

Name:				
	Last	First	MI	
Birthdate:	Age:	Male:	ale:	
Address:		City:	State:	Zip:
		TB History		
Documentation	of Prior TB Test: Yes	No Date:	Result:	
Documentation (of Prior TB Treatment C	ompletion: Yes 🗌 No		
		Symptoms		
	<u> </u>		Night Sweats Unusua	_
If yes to any of the	he above, please specif	y for how long:		
		Risk Assessmer	nt	
Stero Pulm Population Risk:	oid/immunosuppressiventionary Scilicosis Into	emedication	Ibstance abuse Diabe c Renal Failure Cance Age <5yrs TB Expos lity Nursing Home	r/Leukemia sure
		TB Testing		
Current Medicat	ions:		Recent Vaccina	tions: Yes No
TST Date:	Time:R	ead Date:Re	sult (mm):Positi	ve: Negative:
PPD Solution Lot	:#: <u> </u>			
		Consent		
I consent to a	a TB test for tuberculosi	s for myself.		
☐ I consent to a	OR a TB test for tuberculosi	s for my child,		
Signature:		Date:		

Follow-up for Positive TB Test

Chest Radiograph

All persons with a positive TB test should receive a chest radiograph. Chest radiographs help differentiate between LTBI and pulmonary TB disease.

Key Points

- Persons \geq 5 years of age should have a posterior-anterior view radiograph.
- Children under 5 years of age should have both posterior-anterior and lateral views.
- Periodic follow-up radiographs are not indicated regardless of whether treatment is completed except in unusual circumstances (e.g, contacts to patients with drug resistant TB).

Radiographic findings suggestive of active TB include:

- Air-space opacity or consolidation, often referred to as air-space disease
- Interstitial opacity
- Nodules or masses
- Thoracic lymphadenopathy
- Pulmonary cysts or cavities
- Pleural space abnormalities

For more information on TB Chest Radiology see:

http://www.currytbcenter.ucsf.edu/products/product details.cfm?productID=ONL-15

Sputum Examination

Sputum examination is indicated for persons with positive TB test results and either an abnormal chest radiograph or the presence of respiratory symptoms (even when the chest radiograph is normal).

Key Points

- Three consecutive sputums should be collected 8-24 hours apart with one being and early morning sputum.
- Specimens should be refrigerated until sent to the laboratory.
- Order an Acid Fast Bacilli (AFB) smear and culture on each specimen.
- Nucleic Acid Amplification testing (NAAT) may be ordered through the Washington State Public Health Lab (WAPHL). Contact WAPHL at 206-418-5473 for ordering information.

	Tuberculosis Laboratory Diagnostics Summary
AFB Smear AFB Culture	 Tests for the presence of any mycobacterium Results available within 24 hours Provides clue to potential infectivity Does not differentiate between live and dead mycobacterium Performed in most laboratories Gold standard for diagnosing TB Results typically available in 2-8 weeks Only detects live mycobacterium Performed at WAPHL, Harborview, SeaKing PHL, PAML, UW, and
Species Identification	 Performed <u>automatically</u> on positive cultures to determine the type of mycobacterium present (ex. M.tb, M. avium, M. gordonae) One of the following methods is used to identify the species: DNA Probe (AccuProbe) Hsp65 sequencing High Performance (or Pressure) Liquid Chromatography (HPLC)
Nucleic Acid Amplification Test (NAAT)	 Detects TB DNA Performed after AFB smear, if ordered (more sensitive on smear positive specimens) A positive NAAT is considered a confirmed case of TB A negative NAAT does not rule out TB Results available in 24-72 hours Does not differentiate between live and dead mycobacterium Two methods for NAA testing include: Polymerase Chain Reaction (PCR) performed at WAPHL Hsp65 Sequencing performed at UW
Drug Sensitivity Testing	 First-line (SIRE and usually PZA) performed <u>automatically</u>, using MGIT instrument, on culture positive specimens Available within 30 days of culture positive result Performed at Harborview, PAML, or WAPHL Second-line performed at WAPHL or CDC using plate or Agar Proportion Method, if first-line resistance detected
Drug Resistance Mutation Detection	 Detects common mutations located within specific regions of TB DNA Performed when requested on NAAT or culture positive specimens Two methods for detecting mutations include: Drug Resistance Screening by Sequencing (DRSS) performed at WAPHL Molecular Detection of Drug Resistance (MDDR) performed at CDC Detected mutation does not always mean total resistance to the drug(s)
Genotyping	 Performed <u>automatically</u> on culture positive specimens Determines the strain of TB and whether it matches other strains of TB Performed by a CDC contracted lab in Michigan

Acronyms: Washington State Public Health Lab (WAPHL), Seattle and King County Public Health Lab (SeaKing PHL), Pathology Associates Medical Laboratory (PAML), Univiersity of Washington (UW), Centers for Disease Control and Prevention (CDC), Streptomycin, Isoniazid, Rifampin, Ethambutol (SIRE), Pyrazinamide (PZA)

Section Two: Initiating Treatment

Decision to Treat

The decision to initiate or forego treatment for LTBI should be made by weighing a person's risk for progression to active TB disease, risk for potentially harmful side effects from the medication, and likelihood of patient adherence. The following tool may help you estimate the risk of active TB for persons with a TST reaction > 5mm and/or a positive IGRA: http://tstin3d.com/en/calc.html

Key Points

- There is no age cutoff for LTBI treatment
- Never begin treatment for LTBI until active TB disease is ruled out

Choosing a LTBI Treatment Regimen

Each LTBI treatment regimen differs regarding risk for side effects, drug-drug interactions, and length of treatment. With this in mind, an appropriate regimen should be chosen after considering a person's health status, other medications prescribed, and life circumstances.

The following printable one-page table summarizes the different LTBI Treatment Regimens:



Latent Tuberculosis Infection (LTBI) Treatment Regimens

Regimen	Dosages		•	Comments
Rifampin Daily x 4 months Isoniazid (INH) and Rifapentine Once weekly x 12 weeks 3HP "12 dose regimen"	Pediatric dosage: 15 Target Duration: 120 of Isoniazid 15 mg/ky nearest 50 or 100 my tablets Kg Less than 45 kg 45 - 55 kg 55 kg or more Rifapentine once we Preparation: 150 mg Kg 10.0-14.0 kg 14.1-25.0 kg 25.1-32.0 kg 32.1-49.9 kg ≥50.0 kg	r 300mg capsules. ally 600 mg ace daily for adults -20mg/kg/d (600mg doses within 180 d g per dose once we g (max 900 mg). F Lbs 98 or less 99 - 120 121 or more reekly dosage tablets Lbs 22-31 32-55 56-71 72-110 111 or more	who weigh less than 50 kg. ng maximum) lays eekly, rounded up to the For example, using 300-mg Dosage 600 mg 750 mg 900 mg max Dosage 300mg 450mg 600mg 750mg 900mg max	Higher rates of treatment completion Lower rates of side effects, especially drug-induced hepatitis Self-administered Caution: drug-drug interactions Monthly symptom review for side effects Higher rates of treatment completion Lower rates of side effects, especially drug-induced hepatitis Can be self-administered Shortest LTBI regimen Caution: drug-drug interactions due to rifapentine Monthly symptom review for side effects If patient has diabetes, HIV, renal failure, alcoholism, poor mutrition or is pregnant/breast-feeding, administer vitamin B6 50 mg weekly
Isoniazid Daily x 6 – 9 months	Target Duration: 12 doses within 16 weeks Preparation: 100mg or 300mg tablets. Dosage: Adults: 5 mg/kg per dose (300 mg max) Children: 10-15mg/kg per dose (300mg max) Consider 200 mg once daily for adults 40 kg or less Target duration: >180 doses within 9 months acceptable; 270 doses within 12 months preferred.		ng max) 40 kg or less	First choice for children < 2 years (crush pills as suspension is poorly tolerated) Be aware of INH-related hepatotoxicity Poor adherence due to longer duration of INH Self-administered Monthly symptom review for side effects If patient has diabetes, HIV, renal failure, alcoholism, poor nutrition or is pregnant/breast-feeding, administer vitamin B6 25-50 mg daily
Isoniazid Twice Weekly x 6 – 9 months	Dosage: Adults: 15mg/kg per dose (900 mg max) Children: 20-30mg/kg/dose (900 mg max) Target duration: >52 doses acceptable within 9 months; 76 doses preferred within 12 months.		max)	Be aware of INH-related hepatotoxicity The use of directly observed therapy is highly recommended and thus it requires sustained resource utilization for 6 – 9 months Consider 3HP instead for children > 2 years and adults Monthly symptom review for side effects If patient has diabetes, HIV, renal failure, heavy alcohol use, poor nutrition or is pregnant/breast-feeding, administer vitamin B6 50 mg with INH

Key Points

- Intermittent therapy (anything other than seven days per week) should be administered by directly observed therapy (DOT), meaning a trained health care provider observes the person swallowing each dose of medication
- HIV + persons on antiretroviral therapy should not be dosed intermittently and should not be placed on Rifampin
- Use of liquid Isoniazid in children may cause diarrhea. Crushing the tablets is a common alternative

For additional information on TB drugs, side effects, and contraindications see: http://www.currytbcenter.ucsf.edu/tbdruginfo/

Several drug-interaction tools are available online (both free and paid versions). A suggested program is Lexi-Comp available at: http://www.lexi.com/institutions/products/pda/lexi-drugs-lexi-interact/http://uptodate.com

Baseline Laboratory Monitoring

Baseline laboratory testing (measurements of serum AST, ALT and bilirubin) are not routinely necessary unless the patient has any of the following factors:

- Liver disorders
- History of liver disease (hepatitis B or C, alcoholic hepatitis, or cirrhosis)
- Regular use of alcohol
- Risks for chronic liver disease
- HIV infection
- Pregnancy or the immediate postpartum period (within 3 months of delivery)
- Intake of additional hepatotoxic medicationsⁱ

Patient Education and Consent

Upon initiating treatment it is important that the patient fully understand the benefits and risks of LTBI therapy. Patient education should include:

- basic disease process (LTBI vs TB disease)
- basis for their LTBI diagnosis (TB test result, x-ray result, etc.)
- rationale for medication in the absence of symptoms or radiographic abnormalities
- possible side effects of the medication
- stop taking treatment and seek medical attention immediately if symptoms of hepatitis develop

For resources and additional information on TB patient education see: http://ethnomed.org/patient-education/tuberculosis

Once the patient has been informed of the benefits and risks of LTBI therapy and agrees to start treatment, it is important to obtain documentation of the patient's agreement. The following form is an example of a treatment consent form:

Consent for LTBI Treatment

The following has been explained to me:

- Tuberculosis (TB) can spread through the air and be breathed in by anyone causing them to become infected with TB.
- My blood test and x-ray determined that I have been infected with TB.
- My TB <u>infection</u> does not cause me to feel sick and I cannot spread TB to others.
- My TB <u>infection</u> is treated with 4-9 months of TB antibiotics, taken daily, with monthly clinical check-up's.
- Without treatment, I have a 10% chance of developing active TB disease sometime in my life.
- If I develop active TB <u>disease</u> I may feel sick and spread TB to others.
- It is important that I finish my entire course of TB antibiotics to minimize my risk of developing active TB disease.
- It is my responsibility to come to the clinic, in person, monthly to refill my TB antibiotic and be evaluated for side effects of the medications. If I cannot keep my appointment I will notify the clinic to reschedule my appointment.
- I realize that a friend or family member will not be allowed to pick up my medication for me.
- I agree to communicate with a nurse if I have any side effects or problems with TB medications, if I develop any signs or symptoms of TB (cough, fever, night sweats, losing weight), and if I stop taking the medication.
- If I have dark urine, yellowing skin or eyes, or experience other side effects of the medication, I will stop taking the medication and seek medical care right away.

I have had the opportunity to ask questions and have my questions answered.

•	s infection but will notify my doctor or the TB g more than 3 weeks, blood in my sputum, eats, fevers, or unusual tiredness.
I agree to be treated for my TB infect	tion.
I have received a copy of this docum	ent.
Client or Guardian's Signature	 Date

Special Situations

HIV-Infected Individuals

- HIV- infected individuals should be treated with a 9-month regimen of INH.
- Rifampin is contraindicated in HIV-infected persons being treated with certain combinations of antiretroviral drugs. For more information see:

http://www.cdc.gov/tb/publications/guidelines/TB_HIV_Drugs/recommendations03.htm_and http://www.currytbcenter.ucsf.edu/ltbihiv/

<u>Pregnancy</u>

- Use a shield to when performing a chest radiograph to rule out TB disease
- After TB disease is excluded wait until 2-3 months post partum to initiate treatment unless the woman is HIV-infected or a recent contact to an infectious case
- Isoniazid is the preferred drug and supplementation with 10-25mg/d of pyridoxine (vitamin B6) is recommended

Breastfeeding

 Supplementation with 10-25 mg/d of pyridoxine (vitamin B6) is recommended for nursing women and for breastfed infants

Infants and Children

- Infants and children under 5 years of age with LTBI have been recently infected and, therefore, are at high risk for progression to disease
- Risk of INH-related hepatitis in infants and children is minimal
- Directly observed therapy (DOT) should be considered

Section Three: Case Management

Patient Monitoring

In Washington State, to ensure safe and efficacious treatment for LTBI, the patient should be seen by the health care provider who is managing their treatment monthly. This visit should include clinical monitoring, laboratory testing (if needed), and ongoing patient education.ⁱ

Clinical Monitoring

The following assessment form is an example of a documentation tool for use during the patients monthly visits. This form is meant to be printed double sided:

LTBI Case Management: Monthly Patient Assessment

Are you having any of the following symptoms?				
YES	NO	 Cough Coughing up blood or phlegm Sweating heavily at night Weight loss Feeling unusually tired Fever Poor appetite Nausea or vomiting Abdominal discomfort, bloating or cramping Yellowing of the skin or the whites of your eyes Numbness, tingling or aching of the hands or feet Rash Hives or itching Joint pain Dark urine Have you used any Tylenol or acetaminophen since your last appointment? Have you used alcohol or drugs since your last appointment? 		
		If yes, how much?		
		Date of your last period: 22. Are you using birth control? 23. Have you been taking your TB medication as directed? 24. Do you want an interpreter to discuss a problem related to your TB medication?		
I have answered the above list of questions to the best of my knowledge. X Patient/ Parent Signature:				
1	Use Or t Name:	nly: Birthdate:Visit #:Date://		

NURSE TO COMPLETE THIS SECTION:

NURSING ASSESSMENT:	
 ☐ Intake assessment completed (see form) ☐ No jaundice ☐ Skin is clear ☐ Patient is taking medication as directed. ☐ No change in meds since last visit 	 No change in health status since last visit Negative for S/S of active TB disease Using appropriate birth control Questionnaire was reviewed, no concerns identified.
NURSING INTERVENTIONS:	
 ☐ Interpreter used per request or need ☐ Hepatic function panel obtained ☐ Hold medication ☐ TB Medical Consultant notified ☐ Recommended PYRIDOXINE to medication regimen ☐ Switched medication ☐ Changed dosage of medication ☐ End of tx education and documentation given 	 ☐ Checked new Rx/herb/vitamin for drug interactions ☐ Pregnancy test obtained ☐ Referred to Inland Imaging - CXR ☐ Obtained sputum for AFB smear and culture ☐ Other: ☐ Transferred pt to:
Obtained Weight Next appointment schedu	uled for one month or
☐ Medication started/refill given ☐ Completed	medication
Nurse Signature	Date

Laboratory Testing

Routine periodic retesting is only recommended for persons who had abnormal baseline results and other persons at risk for hepatic disease. Laboratory testing is also recommended if patients have symptoms suggestive of hepatitis. AST or ALT elevations up to 5 times normal can be accepted if the patient is free of hepatitis symptoms, and up to 3 times normal if there are signs or symptoms of liver toxicity.

Section Four: Dispositioning the Patient

Determining Treatment Completion

When determining treatment completion, both the number of doses and number of months should be considered. If the patient cannot complete the required number of doses within the maximum amount of time then treatment is not considered complete and should be restarted or discontinued.

The following chart is a tool to assist in determining treatment completion:

Drug(s)	Typical Duration	Frequency	Total doses required	Maximum time to complete
Isoniazid (INH)	9 months	Daily	270	12 months
		Twice weekly	76	12 months
	6 months	Daily	180	9 months
		Twice weekly	52	9 months
Rifampin (RIF)	4 months	Daily	120	6 months
Isoniazid (INH) and Rifapentine (RPT)	3 months	Once weekly	11-12	4 months

Documentation

Patients should receive documentation of TST or IGRA results and treatment completion that includes name, dates, chest radiograph results, and dosage and duration of medication. The patient should be instructed that he or she should present this documentation any time future testing is required.

The following form is an example of treatment completion documentation:

Tuberculosis Treatment Summary

Date of report:			
Name:	Date of birth:		
QuantiFERON-G	old TB Test	TB S	Skin Test
Date		Date	JKIII 103t
Reading		Reading	
<u> </u>			
	Ima	aging	
Initial Imaging Date			
Type of Imaging			
Reading			
Follow-up Imaging Da	nte		
Type of Imaging			
Reading			
	AFD Mic	wahiala mu	
1 st AFB Smear + Date:		robiology 1 st AFB Culture + Date	e: or N/A
AFB Smear + Date: AFB Smear – x 3 Date:			
AFB Silleai – X 3 Date. Specimen:	OI IN/A	1 st AFB Culture – Date	: or N/A
эресппеп.		Specimen:	
	Medicati	on History	
Directly Observed	Videophone	Self-administered	Combination
Drug	Dosage	First Dose	Last Dose
Isoniazid (INH)			
Rifampin (RIF)			
Ethambutol (EMB)			
Pyrazinamide (PZA)			
_		_	
Treatment Complete:		Treatment Not	t Complete: 🔲

If you have further questions regarding your Tuberculosis treatment, please contact the XXX-XXXX.

Education

Providers should re-educate patients about the signs and symptoms of TB disease and advise them to contact the medical provider if he or she develops any of these signs or symptoms. Patients should also be reminded that their TB test will likely always be positive despite completing treatment and to avoid additional TB testing by showing documentation of completing treatment.

Section Five: Additional Resources

TB Contacts

State

http://www.doh.wa.gov/AboutUs/ProgramsandServices/DiseaseControlandHealthStatistics/Infectious Disease/TuberculosisStaff.aspx

Local

http://www.doh.wa.gov/AboutUs/PublicHealthSystem/LocalHealthJurisdictions.aspx

References

ⁱ CDC. Latent tuberculosis infection: a guide for primary healthcare providers. 2010.

[&]quot;http://www.cdc.gov/tb/publications/factsheets/testing/TB_testing.htm